Literature DB >> 22576581

Medical conditions and risk of adult myeloid leukemia.

Kimberly J Johnson1, Cindy M Blair, James M Fink, James R Cerhan, Michelle A Roesler, Betsy A Hirsch, Phuong L Nguyen, Julie A Ross.   

Abstract

PURPOSE: Although a few previous studies have reported positive associations between adult myeloid leukemia and a history of certain medical conditions, the etiology of most cases remains largely unknown. Our purpose was to examine associations between certain medical conditions and adult myeloid leukemia.
METHODS: Using logistic regression, we evaluated associations between 16 self-reported medical conditions and myeloid leukemia in a case-control study of 670 cases [including 420 acute myeloid leukemia (AML) and 186 chronic myelogenous leukemia (CML)] and 701 population-based controls.
RESULTS: We observed significant positive associations between AML and ulcerative colitis (odds ratio (OR) = 3.8; 95 % confidence interval (CI), 1.1-13) and between CML and peptic ulcer (OR = 2.0; 95% CI, 1.1-3.8). A personal cancer history increased both AML (OR = 2.6; 95% CI, 1.7-3.9) and CML (OR = 3.5; 95% CI, 2.0-5.8) risk even after excluding individuals who reported prior radiation and/or chemotherapy treatment.
CONCLUSION: Certain inflammatory medical conditions and a personal history of cancer, independent from therapy, are associated with an increased risk of myeloid leukemia.

Entities:  

Mesh:

Year:  2012        PMID: 22576581      PMCID: PMC3571859          DOI: 10.1007/s10552-012-9977-y

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  24 in total

1.  A review of human carcinogens--Part A: pharmaceuticals.

Authors:  Yann Grosse; Robert Baan; Kurt Straif; Béatrice Secretan; Fatiha El Ghissassi; Véronique Bouvard; Lamia Benbrahim-Tallaa; Neela Guha; Laurent Galichet; Vincent Cogliano
Journal:  Lancet Oncol       Date:  2009-01       Impact factor: 41.316

2.  Gastrointestinal lesions and Helicobacter pylori in patients with myeloproliferative disorders.

Authors:  Ali O Karaoglu; Gurhan Kadikoylu; Vahit Yukselen; Mehmet H Yasa; Zahit Bolaman
Journal:  Saudi Med J       Date:  2004-12       Impact factor: 1.484

Review 3.  Late effect of atomic bomb radiation on myeloid disorders: leukemia and myelodysplastic syndromes.

Authors:  Hideki Tsushima; Masako Iwanaga; Yasushi Miyazaki
Journal:  Int J Hematol       Date:  2012-02-28       Impact factor: 2.490

4.  Risk of haematopoietic cancer in patients with inflammatory bowel disease.

Authors:  J Askling; L Brandt; A Lapidus; P Karlén; M Björkholm; R Löfberg; A Ekbom
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

5.  Response rates among control subjects in case-control studies.

Authors:  M L Slattery; S L Edwards; B J Caan; R A Kerber; J D Potter
Journal:  Ann Epidemiol       Date:  1995-05       Impact factor: 3.797

6.  Acute myelogenous leukemia in patients with ulcerative colitis.

Authors:  T L Fabry; D B Sachar; H D Janowitz
Journal:  J Clin Gastroenterol       Date:  1980-09       Impact factor: 3.062

7.  Chronic myeloid leukemia after treatment with 131 for thyroid carcinoma.

Authors:  Kang-Ling Wang; Liang-Yu Lin; Po-Min Chen; Hong-Da Lin
Journal:  J Chin Med Assoc       Date:  2005-05       Impact factor: 2.743

8.  Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.

Authors:  J Askling; C M Fored; E Baecklund; L Brandt; C Backlin; A Ekbom; C Sundström; L Bertilsson; L Cöster; P Geborek; L T Jacobsson; S Lindblad; J Lysholm; S Rantapää-Dahlqvist; T Saxne; L Klareskog; N Feltelius
Journal:  Ann Rheum Dis       Date:  2005-04-20       Impact factor: 19.103

9.  Treatment-associated acute myeloid leukemia in a patient with Crohn's disease on 6-mercaptopurine.

Authors:  Koushik K Das; Ha Thanh Nishino; Andrew T Chan
Journal:  Inflamm Bowel Dis       Date:  2010-09       Impact factor: 5.325

10.  Cancer risks in ulcerative colitis patients.

Authors:  Kari Hemminki; Xinjun Li; Jan Sundquist; Kristina Sundquist
Journal:  Int J Cancer       Date:  2008-09-15       Impact factor: 7.396

View more
  7 in total

Review 1.  Epidemiology of MPN: what do we know?

Authors:  L A Anderson; M F McMullin
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

2.  Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia.

Authors:  N Gunnarsson; M Höglund; L Stenke; S Wållberg-Jonsson; F Sandin; M Björkholm; A Dreimane; M Lambe; B Markevärn; U Olsson-Strömberg; H Wadenvik; J Richter; A Själander
Journal:  Leukemia       Date:  2016-03-08       Impact factor: 11.528

3.  Personal history of autoimmune disease and other medical conditions and risk of myelodysplastic syndromes.

Authors:  Amy M Linabery; Michelle A Roesler; Michaela Richardson; Erica D Warlick; Phuong L Nguyen; Adina M Cioc; Jenny N Poynter
Journal:  Cancer Epidemiol       Date:  2022-01-05       Impact factor: 2.984

4.  Risk of adult acute and chronic myeloid leukemia with cigarette smoking and cessation.

Authors:  Jessica R B Musselman; Cindy K Blair; James R Cerhan; Phuong Nguyen; Betsy Hirsch; Julie A Ross
Journal:  Cancer Epidemiol       Date:  2013-05-02       Impact factor: 2.984

Review 5.  Frontline therapy of AML: should the older patient be treated differently?

Authors:  James M Foran
Journal:  Curr Hematol Malig Rep       Date:  2014-06       Impact factor: 3.952

6.  NSAID consumption and risk of acute myeloid leukemia: a national population-based case-control study.

Authors:  Lene Sofie Granfeldt Østgård; Mette Nørgaard; Lars Pedersen; René Østgård; Lone Smidstrup Friis; Claudia Schöllkopf; Marianne Tang Severinsen; Claus Werenberg Marcher; Bruno C Medeiros; Morten Krogh Jensen
Journal:  Cancer Manag Res       Date:  2018-10-29       Impact factor: 3.989

Review 7.  What Clonal Hematopoiesis Can Teach Us About MDS.

Authors:  Irenaeus C C Chan; Brian J Wiley; Kelly L Bolton
Journal:  Front Oncol       Date:  2022-02-08       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.